mitoxantrone has been researched along with Ductal Carcinoma in 1 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, B | 1 |
| Fu, D | 1 |
| Xu, Q | 1 |
| Cong, X | 1 |
| Wu, C | 1 |
| Zhong, X | 1 |
| Ma, Y | 1 |
| Lv, Z | 1 |
| Chen, F | 1 |
| Han, L | 1 |
| Qian, M | 1 |
| Chin, YE | 1 |
| Lam, EW | 1 |
| Chiao, P | 1 |
| Sun, Y | 1 |
1 other study available for mitoxantrone and Ductal Carcinoma
| Article | Year |
|---|---|
The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Non-Small-Cell Lung; | 2018 |